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Abstract
Exocrine pancreatic cancer (pancreatic ductal adenocarcinoma) is one of the leading causes of cancer deaths in the western
world, accounting for 5% of all cancer-related deaths. Only a small percentage of patients with pancreatic cancer are able to
undergo potentially curative resection, even in specialized centres, and prognosis remains poor after successful surgery. Over
the last few years efforts have been directed towards the development of adjuvant therapies in attempts to improve outcome.
The main trials of adjuvant chemotherapy, chemoradiotherapy and chemoradiotherapy with follow-on chemotherapy are
described in this paper, followed by the results of the ESPAC-1 trial and the status of ESPAC-2 and -3 trials.
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Introduction
Exocrine pancreatic cancer (pancreatic ductal adeno-
carcinoma) is one of the leading causes of cancer
deaths in the western world, accounting for 5% of all
cancer-related deaths [1]. Worldwide there are
227 000 deaths per year. Only 1015% of patients
with pancreatic cancer are able to undergo potentially
curative resection, even in specialized centres [2].
Following successful surgery, prognosis remains poor,
as the median survival is around 1315 months and
the 5-year survival rate is 1520% [3,4]. Attempts at
more radical pancreatic resections and extended
lymphadenectomy, although feasible without exces-
sive morbidity and mortality, have failed to produce
any convincing improvement in survival [5]. This may
be due, in part, to the fact that the majority of disease
recurrences occur locally or in the liver [68]. Over
the last few years, therefore, efforts have been
directed towards the development of adjuvant thera-
pies in an attempt to improve outcome. The main
trials of adjuvant chemotherapy, chemoradiotherapy
and chemoradiotherapy with follow-on chemotherapy
will be described, followed by the results of the
ESPAC-1 trial and the status of ESPAC-2 and -3
trials.
Systemic chemotherapy
Until the European Study Group for Pancreatic
Cancer (ESPAC) 1 trial [9,10], there were few
adequately powered, randomized studies assessing
adjuvant therapy in pancreatic cancer (Table I). This
multicentric, randomized, two-by-two factorial design
trial accrued 541 patients between February 1994 and
June 2000 from 61 cancer centres in 11 countries.
Besides the two-by-two factorial design allocation (i.e.
observation, chemoradiotherapy alone, chemotherapy
alone and both), randomization outside of the two-by-
two factorial design, into one of the main treatment
comparisons (i.e. chemotherapy versus no chemother-
apy and chemoradiotherapy versus no chemora-
diotherapy) was permitted.
Chemotherapy was administered using 5-fluo-
rouracil (5-FU) given intravenously at a dose of
425 mg/m2 daily for 5 days, over a period of 6
months. In the interim analysis of 541 patients after
a median follow-up of 10 months [9], there was
evidence of survival benefit for adjuvant chemother-
apy. The median survival was 19.7 months in the
238 patients with chemotherapy versus 14 months in
the 235 patients who did not receive chemotherapy
(p/0.0005).
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Influence of resection margin on survival was
assessed, with 101/541 (19%) having positive micro-
scopic resection margins (R1) [5]. The median
survival was 10.9 months in those who had R1
resection versus 16.9 months for patients with R0
resection, establishing resection margin status as an
influential prognostic factor. Irrespective of the R0/R1
status, there was survival benefit for chemotherapy,
with R0 patients having longer survival following
chemotherapy in comparison with the group that
did not receive chemotherapy. This difference was
less apparent for the smaller subgroup of R1 patients,
despite there being no significant heterogeneity be-
tween the two, i.e. R0 and R1 groups.
The final analysis of the ESPAC-1 trial assessed the
289 patients randomized using the two-by-two factor-
ial design, and followed up for a median of 47 months
[10]. The conclusions were similar, with the median
survival being 20.1 months among the 147 patients
who were assigned to the chemotherapy group and
15.5 months among the 142 patients who did not
receive chemotherapy (p/0.009) (Figure 1). The
2-year and 5-year survival estimates were 40% and
21%, respectively, in the chemotherapy group and
30% and 8% in the group without chemotherapy. A
significant survival benefit for chemotherapy was
demonstrated, irrespective of whether the patients
were randomized to receive chemoradiotherapy or
not. Prognostic factors that had significant adverse
influence on survival were the differentiation of
tumours (pB/0.001), lymph nodal involvement (pB/
0.001), and a maximum tumour size of /2 cm (p/
0.003). Prognostic factors of borderline significance
were current smoking (p/0.07), R1 status (p/0.10),
and presence of involved adjacent structures on
histologic analysis (p/0.10). The median time to
recurrence was 15.3 months in the chemotherapy
group versus 9.4 months in patients who did not
receive chemotherapy (p/0.02).
The influence of the type of surgery and the
presence of complications on survival (in conjunction
with clinicopathological variables) was investigated
using the Cox proportional hazard model [11]. The
final model was based on 481 ESPAC-1 patients who
had undergone either Kausch-Whipple (KW) or
pylorus-preserving KW (PPKW). Neither the type
of surgery nor the presence/absence of complications
significantly influenced survival. Benefit for che-
motherapy was demonstrated, irrespective of these
two factors. Based on these findings, it is recom-
mended that the occurrence of postoperative compli-
cations should not deter patients from participating in
adjuvant treatment trials.
Bakkevold et al. [12] from Norway conducted a
much smaller randomized controlled trial (RCT)
between 1984 and 1987, randomizing 61 radically
resected patients to receive either postoperative ad-
juvant combination chemotherapy or no chemother-
apy, i.e. control group. Of the 61 patients, 47 hadT
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Adjuvant treatment 353
pancreas cancer while the rest had periampullary
cancer. The chemotherapy regimen employed com-
prised 5-FU (500 mg/m2), doxorubicin (40 mg/m2)
and mitomycin C (6 mg/m2) given every 3 weeks for a
total of six cycles. Chemotherapy was associated with
an increased median survival (23 months versus 11
months in the control group; p/0.04) and delay in
the incidence of recurrence in the first 2 years after
radical surgery, but an increased cure rate was not
observed. Difficulties with this regimen included
substantial toxicity: of the 30 patients randomized to
receive chemotherapy only 13 managed to complete
the six courses. Moreover, after the first course, 16 of
22 patients needed hospitalization for toxic side
effects. Also, as the study analysis (survival) pooled
patients with pancreas and periampullary cancer, it is
difficult to draw conclusions on the usefulness of
adjuvant chemotherapy solely for pancreas cancer.
Another RCT from Japan by Takada et al. [13]
shares the drawbacks of the Norwegian trial, as this
study also enrolled patients with pancreatic, gall
bladder, bile duct and ampulla of Vater cancers.
However, analysis was performed for each specific
disease. Between April 1986 and June 1992, 508
patients were enrolled, including 173 resected pan-
creatic cancer patients. Patients were assigned to
receive either combination chemotherapy (mitomycin
C and 5-FU) or to the control group. The chemother-
apy group received mitomycin C (6 mg/m2 i.v.) at the
time of surgery and 5-FU (310 mg/m2 i.v.) in two
courses for 5 consecutive days during postoperative
weeks 1 and 3, followed by 5-FU (100 mg/m2 orally)
daily from postoperative week 5 until disease recur-
rence. After ineligible patients were excluded, data
from 158 patients with pancreatic cancer was analysed
(58 in the chemotherapy group and 60 in the control
group). The 5-year survival rate was 11.5% in the
chemotherapy group and 18.0% in the control group,
and there was no statistically significant difference in
survival between the two groups. Likewise, there was
no significant difference in the disease-free survival
time or time to recurrence. The equivocal results
between the chemotherapy and control group could
have been due to the use of oral 5-FU, which because
of its hepatic metabolism has very poor efficacy
compared with intravenously administered 5-FU or
specially designed oral fluoropyrimidines [14].
In a recent RCT (July 1998 to December 2004),
Neuhaus et al. [15] randomized 368 patients to
receive either adjuvant chemotherapy with gemcita-
bine or observation following resection of pancreatic
cancer. Preliminary results have revealed improved
survival in the gemcitabine arm (14.2 months)
compared with the observation arm (7.5 months;
pB/0.05). Final results of this trial are expected in late
2005.
Kurosaki and Hatekayama [16], in a prospective
trial (19982003), enrolled 21 patients with node-
positive pancreatic cancer following curative resection
into a gemicitabine monotherapy adjuvant trial. Nine
patients received chemotherapy with biweekly gemci-
tabine (1000 mg/m2), while the remaining 12 patients
only underwent resection. Chemotherapy was well
tolerated. The overall 1- and 2-year cumulative
survival rates of the chemotherapy group were 86%
and 50%, respectively, while those of the surgery only
group were 75% and 0%, respectively. The median
survival of the chemotherapy group was 20.3 months
versus 15.4 months in the surgery only group (p/
0.0084). The disease-free interval was also signifi-
cantly greater in the chemotherapy group compared
with the surgery-alone group (p/0.0244). Splinter et
al. [17], in the 1980s, examined the use of 5-FU,
doxorubicin and mitomycin C (FAM) in 16 patients
and compared them with a historical control group of
36 patients. The 3-year survival rate was 24% for the
FAM group versus 28% in the control group, imply-
ing no benefit from adjuvant chemotherapy.
Figure 1. KaplanMeir estimates of survival according to whether
or not patients received chemoradiotherapy (A) or chemotherapy
(B) in the ESPAC-1 trial final results. CRT, chemoradiotherapy;
CT, chemotherapy.
354 A. Sultana et al.
Baumel et al. [18] reported a retrospective series
involving 787 patients who had undergone pancreatic
resection for cancer. In all, 43 patients were given
postoperative chemotherapy, although there was no
standardization of the chemotherapy regimens used.
The median survival time was 12.4 months for
patients in the surgery only arm and 11.5 months
for the adjuvant chemotherapy arm.
Of the few trials looking at the role of adjuvant
chemotherapy, the ESPAC-1 trial is the largest and
not confounded by the inclusion of periampullary/
biliary neoplasms. The findings of this trial are highly
significant and will direct the focus of future studies to
the use of chemotherapeutic agents alone. To address
this issue the ESPAC-3 trial is recruiting patients and
has randomized 122 patients so far to receive either
5-FU or gemcitabine post surgery.
Regional chemotherapy
To reduce the side effects of systemic chemotherapy,
regional delivery of chemotherapeutic agents to the
target site has been carried out (Table II). In one of the
earliest series, Ishikawa et al. [19] directed chemother-
apy to the liver, as this is a common site of treatment
failure following curative resection. Both the hepatic
artery and portal vein were cannulated after extended
pancreatectomy and 5-FU was given by continous
infusion via these indwelling catheters. Of the 20
patients who were treated thus, the 3-year survival
rate was 54%, and the cumulative rate of death from
hepatic metastasis was 8%. The drawback of this study
was that the results were compared to historical
controls, against whom the regional treatment regimen
was superior. In a later publication by the same group
[20], a comparison was made between 27 patients who
received liver perfusion chemotherapy against 67
patients who did not. All patients had undergone
extended pancreatectomy between 1987 and 1995.
The cumulative survival rate was significantly better in
the regional chemotherapy group at 1 year (92% in the
chemotherapy group versus 62% in the surgery arm;
pB/0.05) and 3 years (51% vs 35%; pB/0.05) but there
was no difference at 5 years (41% vs 25%).
In 1994, Ozaki et al. [21] reported a 5-year survival
of 32% in 24 patients who had resection and who
were then further treated with intraoperative radio-
therapy (IORT) as well as regional chemotherapy. In a
later publication [22] in 2000, they published their
results for 30 patients (November 1983 to January
1993) treated by extended pancreatectomy, IORTand
hepatic artery or portal vein infusion of mitomycin C
followed by systemic bolus administration. The 5-year
survival rate for 27 patients (excluding 3 with
metastases to the liver, peritoneum, or lung) was
31%, with a median survival of 31.1 months. In a
further analysis of 19 patients with regional nodal
metastases, the 1-year survival rate was 95%, 3-year
survival rate 50% and 5-year survival rate 28%. T
a
b
le
II
.
A
d
ju
va
n
t
re
g
io
n
a
l
th
er
a
p
y
fo
r
p
a
n
cr
ea
ti
c
ca
n
ce
r.
S
er
ie
s
Y
ea
r
n
R
eg
im
en
M
ed
ia
n
su
rv
iv
a
l
(m
o
n
th
s)
A
ct
u
a
ri
a
l
su
rv
iv
a
l
(%
)
1
y
ea
r
A
ct
u
a
ri
a
l
su
rv
iv
a
l
(%
)
3
y
ea
r
A
ct
u
a
ri
a
l
su
rv
iv
a
l
(%
)
5
ye
a
r
Is
h
ik
aw
a
et
a
l.
[1
9
]
1
9
9
4
2
0
H
A
I

/
P
V
I
(5
-F
U
)


5
4

O
za
k
i
et
a
l.
[2
1
]
1
9
9
4
2
4
IO
R
T

/
H
A
I

//

/
P
V
I
(M
M
C
)



3
2
L
in
k
et
a
l.
[2
3
,
2
4
]
1
9
9
7
2
0
C
A
I
2
1



2
9

9
.3



Is
h
ik
aw
a
et
a
l.
[2
0
]
1
9
9
7
2
7
H
A
I

/
P
V
I
(5
-F
U
)
9
2
5
1
4
1
6
7
6
2
(p
B
/0
.0
5
)
3
5
(p
B
/0
.0
5
)
2
5
(p

/n
s)
B
eg
er
et
a
l.
[2
6
]
1
9
9
9
2
4
C
A
I(
M
X
/5
-F
U
/C
P
)
2
3


5
4
(4
y
ea
r;
R
0
re
se
ct
io
n
)
2
5

1
0
.5
(p
B
/0
.0
0
1
)
9
.5
(4
y
ea
r;
R
0
re
se
ct
io
n
)
O
za
k
i
et
a
l.
[2
2
]
2
0
0
0
2
7
3
1
.1
3
1
%
P
a
p
a
ch
ri
st
o
u
et
a
l.
[2
5
]
2
0
0
3
3
1
C
A
I
(M
X
/5
-F
U
/C
P
)
2
1
H
A
I,
h
ep
a
ti
c
a
rt
er
ia
l
in
fu
si
o
n
;
P
V
I,
p
o
rt
a
l
v
ei
n
in
fu
si
o
n
;
C
A
I,
co
el
ia
c
a
rt
er
y
in
fu
si
o
n
;
IO
R
T
,
in
tr
a
o
p
er
a
ti
v
e
ra
d
io
th
er
a
p
y
;
5
-F
U
,
5
-f
lu
o
ro
u
ra
ci
l;
M
X
,
m
it
o
x
a
n
tr
o
n
e;
C
P
,
ci
sp
la
ti
n
.
Adjuvant treatment 355
Link et al. [23,24] administered coeliac artery
infusion chemotherapy to 20 patients, 18 with pan-
creatic ductal adenocarcinoma and 2 with cystadeno-
carcinoma. The agents used were mitoxantrone,
5-FU plus folinic acid and cisplatinum given for
6 cycles. The median survival time of the treated
group was 21 months, which was significantly better
(pB/0.0006) compared to 9.3 months in a group of
matched historical controls. Only 15% of patients in
the treated group developed liver metastases, prompt-
ing the authors to conclude that coeliac artery
infusion chemotherapy both improves survival and
decreases/delays the occurrence of liver metastases.
Papachristou et al. [25] likewise administered coeliac
artery infusion chemotherapy to 31 patients, and
found a median survival of 21 months in the treated
group versus 9.3 months in historical controls (pB/
0.0003). The sites of treatment failure were pancreas
bed (50%), intraperitoneal (40%) and liver (15%).
Beger et al. [26] compared results between 26
patients (December 1992 to July 1997) treated with
coeliac artery infusion (CAI) chemotherapy (mitox-
antrone, folinic acid, 5-FU and cisplatin) after resec-
tion and 25 patients (January 1993 to May 1996) who
received no adjuvant chemotherapy after resection.
Systemic side effects were minimal, with 8% WHO
grade III side effects (mainly gastrointestinal ulcera-
tion) and no grade IV toxicity. Excluding two patients
with tail lesions, the remaining 24 patients with head
lesions who received CAI had a median survival of
23 months. This was significantly better than the
10.5 months survival noted in the surgery only group
(pB/0.001). When patients who underwent R0 resec-
tion were analysed, the median survival in the surgery
only arm was 12 months, whereas in the CAI group
the median survival time was not reached after an
observation period of 48 months (pB/0.0001). In the
CAI group, 18 patients developed recurrence of
tumour, with 17% suffering recurrence in the liver
and 83% experiencing local recurrence. Thus,
although CAI provided hepatic protection, its effec-
tiveness in local control was questionable.
Yamaue et al. [27] looked into the effectiveness of
hepatic artery infusional chemotherapy in preventing
liver metastases in the subset of patients with portal
vein invasion. Following radical surgery, this group
has an enhanced risk of developing liver metastases
[2830]. The chemotherapeutic agent used was
determined by assessing the chemosensivity of fresh
human pancreatic cancer cells and the drugs tested
were cisplatin, mitomycin C, adriamycin, 5-FU and
etoposide. Nine patients received chemotherapy while
five did not. None of the patients in the chemotherapy
group developed liver metastases, in contrast to the no
chemotherapy group, wherein all five patients devel-
oped liver metastases. The sites of failure in the
chemotherapy group were locally and in the perito-
neum. The mean survival of patients in the che-
motherapy group was significantly longer (25.6
months) than the control group (9.3 months; pB/
0.05). The problems with this study are the small
numbers and the fact that there was no uniformity in
the agents used.
Results from trials on regional chemotherapy ap-
pear promising in terms of reducing liver metastases
and improving survival, but there are no randomized
controlled trials on this subject. The ESPAC-2 trial is
a multicentre, prospective randomized controlled
phase III trial to compare adjuvant postoperative
intra-arterial chemotherapy and radiotherapy (arm
A) with surgery alone (arm B) in resectable pancreatic
ductal adenocarcinoma and advanced periampullary
cancer. Patients in arm A will receive a total of six
cycles of coeliac artery infusion and a total of 54 Gy
external beam radiation therapy (EBRT). The study
has recruited 70 patients so far and aims to recruit
100 patients overall. It should provide a definitive
answer to the use of regional therapy for pancreatic
cancer in the adjuvant setting.
Chemoradiotherapy
Radiation treatment, either by external beam radia-
tion or intraoperatively, has been given with the idea
of controlling any microscopic residual disease, as
most recurrences following pancreaticoduodenectomy
occur at the site of resection. Radiation has been given
preoperatively, intraoperatively or postoperatively
and often with concurrent chemotherapy both for
radiosensitization and to address systemic microme-
tastases.
Intraoperative radiotherapy
The irradiation of the upper abdomen by EBRT
causes considerable toxicity and IORT can reduce
this, sparing normal tissues. The surrounding tissues
can either be displaced or shielded, thereby allowing
the delivery of larger radiotherapy doses in a single
fraction to volumes harbouring tumour cells.
Fossati et al. [31], in a retrospective study (January
1985 to September 1992), reviewed data from 54
patients with both resectable and unresectable disease
who received IORT and compared them to a control
group of resected patients who did not receive IORT.
Although there was significantly better local control
achieved in resected patients who received IORT
(25% in the IORT group versus 55.8% in the non-
IORT group), this did not translate into improved
survival. Similar results were found by Hiraoka et al.
[32] in 1990, i.e. no increase in survival, when they
compared 15 patients who received IORT after
standard resection against 19 who did not receive
IORT. Subsequently, they performed extended opera-
tion, followed by IORT (from the diaphragm above to
the inferior mesenteric artery below) in 14 patients.
On follow-up, no radiation-related complication oc-
curred and the 5-year cumulative survival was 33.3%.
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Between January 1986 and April 1995, Coquard
et al. [33] treated 25 patients with IORT (dose range
1225 Gy), followed by EBRT (44 Gy) in 20 patients.
Concurrent chemotherapy on days 14 with 5-FU
was given to seven patients. The overall survival at 1
year was 56%, at 2 years was 20% and at 5 years was
10%. Nine patients developed locoregional relapse
while 14 had metastatic disease. The small number
treated, retrospective nature and the lack of a control/
comparison group are the drawbacks of this study.
Zerbi et al. [34] (Table III) compared IORT to
surgery only. The IORT group had a significantly
improved median time to relapse (13 vs 8 months),
better local control (73% vs 43%) and improved
survival at 1 year (49% vs 24%). However, a
prospective study [35] done by the Radiation Therapy
Oncology group found median survival in the IORT
group to be similar to that of conventional treatment.
Reni et al. [36], in a retrospective study, allocated
127 patients to receive IORT following resection,
while 76 had no adjuvant treatment after surgery. In
addition to IORT, 56 patients received EBRT and 82
received chemotherapy (8 different regimens). Local
recurrence occurred earlier in the group with no
IORT (11 months) compared with the group that
received IORT (median 14 months; p/0.02). There
was no significant difference in survival. When data
were further analysed, limited to patients with stage
12 cancer (30 in IORT arm and 19 in surgery
arm), IORT significantly prolonged time to both local
(12 months vs 17.5/ months; p/0.003) and distant
failure (11.5 vs 17.5/ months; p/0.005) and overall
survival (13 vs 18.5 months; p/0.01). The 5-year
survival was 229/10% in the IORT group and 69/6%
in the non-IORT group. Late complications of
chronic upper abdominal pain and gastrointestinal
bleeding were similar in both groups, although
anastomotic stenosis/jejenal stenosis was only seen in
the IORT group.
As most series on IORT are dogged by small
numbers, inclusion of all stages of the disease and
heterogenous treatment strategies, it is difficult to
draw conclusions or make recommendations on
IORT. The one small randomized trial on IORT
[37] was published in abstract form and found no
difference in survival between surgery only and IORT
(median survival 12 months in both groups). At the
present time there is little evidence to support the use
of adjuvant IORT, either alone or in combination with
other forms of treatment.
Postoperative radiotherapy/chemoradiotherapy
In a prospective analysis of 14 patients receiving only
postoperative radiation therapy, Bosset et al. [38]
demonstrated a median survival of 23 months, thus
supporting the use of adjuvant treatment.
In a large multicentric prospective randomized trial
(Table IV), Klinkenbijl et al. [39] compared adjuvantT
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chemoradiotherapy to no adjuvant treatment in both
pancreatic and periampullary cancers. Between Sep-
tember 1987 and April 1995, 218 patients from 29
European centres were enrolled, 108 in the observa-
tion group and 110 in the treatment group. Patients in
the radiotherapy group received split course radio-
therapy with 40 Gy and concurrent 5-FU as contin-
uous infusion, at a dose of 25 mg/kg per 24 hours,
with a maximum daily dose of 1500 mg. In all, 207
patients were evaluable, 103 in the observation group
and 104 in the treatment group. Median survival was
19 months in the observation group and 24.5 months
for the treatment group (log rank p/0.208). In
patients with pancreatic cancer, there was a larger
difference in survival, being 12.6 months in the
observation group and 17.1 months in the treatment
group. Unfortunately the power of the study was
rather weak and the difference in survival approached
borderline significance (p/0.099). That this is likely
to be a true result, rather than a type II statistical error
is borne out by the results of the ESPAC-1 trial [10].
Moreover, 68 (66%) patients in the observation arm
and 67 (65%) in the treatment arm developed
progressive disease. There was no advantage of
adjuvant treatment in progression-free survival of
either the entire group of eligible patients or in
patients with pancreatic head cancer. This suggested
that radiotherapy with 40 Gy does not prevent local
recurrence and that radiotherapy and 5-FU after
curative resection does not offer survival advantage,
despite being safe and well tolerated.
In the ESPAC-1 trial [9], 70 patients were rando-
mized to the chemoradiotherapy arm in the 2/2
factorial design, while a further 68 were randomly
assigned to either chemoradiotherapy or no chemor-
adiotherapy. Chemoradiotherapy was administered as
20 Gy in 10 daily fractions over 2 weeks with 500 mg/
m2 5-FU intravenously on days 13, repeated after
2 weeks. The median survival was 15.5 months in 175
patients who received chemoradiotherapy and 16.1
months in the 178 patients who did not receive
chemotherapy (p/0.24). Thus there was no improve-
ment in 2-year survival benefit achieved following
chemoradiotherapy, and a confounding negative ef-
fect of chemoradiotherapy on the benefit of che-
motherapy alone was apparent. In the final results of
the ESPAC-1 trial [10], which only assessed patients
enrolled in the 2/2 design, the median survival was
15.9 months among the 145 patients assigned to
chemoradiotherapy and 17.9 months among the 144
patients who were not assigned to receive chemor-
adiotherapy (p/0.05). The estimated 5-year survival
was 10% in the chemoradiotherapy arm compared
with 20% in those who did not receive chemora-
diotherapy (p/0.05). The median time to recurrence
was 10.7 months in those assigned to chemora-
diotherapy compared with 15.2 months in those
who did not receive chemoradiotherapy (p/0.04).
The lack of benefit of chemoradiotherapy is similar toT
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that observed in the EORTC trial [39] and one of the
factors could be the delay in administering the follow-
on chemotherapy in patients who received both
treatments, thereby reducing the potential benefit of
chemotherapy that is derived by administering it as
soon as possible after resection.
Neoadjuvant treatment
Neoadjuvant (preoperative) chemoradiotherapy
Preoperative chemoradiation, by providing better
tumour cell oxygenation, might have advantages
over postoperative chemoradiation [40]. Moreover,
with this modality, adjuvant therapy is commenced
early, unlike in the postoperative setting where time to
recovery from a major operation can delay the delivery
of adjuvant treatment. It might also down-stage
tumours, thus reducing positive surgical margins,
and also avoid unnecessary laparotomy in patients
with rapidly progressive disease [41]. A criticism of
preoperative chemoradiotherapy is that in those
patients who progress on treatment, the opportunity
for curative resection may have been missed.
In a prospective, multi-institutional phase II trial,
Hoffman et al. [42] administered preoperative che-
moradiotherapy to 53 patients with resectable pan-
creatic cancer: 5040 cGy radiotherapy was given,
along with mitomycin 10 mg/m2 on day 2 and 5-FU
1000 mg/m2/day continuous infusion on days 25 and
2032. Forty-one patients underwent surgery, while
12 did not owing to death in 1 patient, toxicity in 1,
local progression in 3, distant metastases in 6 and
intercurrent illness in 1 patient. Of the 41 who were
operated upon, 24 underwent resection while the rest
had local extension/distant metastases that precluded
resection. Median survival for the entire group was
9.7 months and for the patients who underwent
resection, was 15.7 months. Treatment toxicity was
primarily haematological, although a comparable
number of patients suffered from biliary tract com-
plications, i.e. obstruction or cholangitis.
Pendurthi et al. [43] retrospectively analysed 25
patients with resected pancreatic carcinoma who
received preoperative chemoradiotherapy versus 18
who received postoperative chemoradiotherapy.
More, though not statistically significant, negative
resection margins were observed in the preoperative
chemoradiotherapy group (28% vs 56%), and also a
significantly greater amount of fibrosis replacing the
tumour in the preoperative chemoradiotherapy group
(70% vs 40%; p/0.0001). There was no significant
survival difference between the two groups (median
20 months vs 25 months; p/0.48), and no difference
in toxicity and efficacy profile. However, 22% of
patients intended for postoperative treatment did
not receive treatment. Likewise, Spitz et al. [44], in
a comparative study between preoperative and post-
operative chemoradiation, found that one-quarter of
eligible patients in the postoperative chemotherapy
group failed to receive treatment owing to prolonged
recovery time. They found no difference in toxicity,
patterns of tumour recurrence and survival between
the two groups.
An Italian study [45] assessed safety and efficacy
of chemoradiotherapy given to both locally advan-
ced (n/20) and resectable (n/8) pancreas cancer
patients. Their protocol comprised 39.6 Gy EBRT
and 5-FU given as continous infusion between days 1
and 4 at 1000 nmg/m2/day. Resected patients received
10 Gy IORT before reconstruction and, subsequently,
six cycles of adjuvant chemotherapy with 5-FU,
mitomycin C and adriamycin. Chemoradiotherapy
was well tolerated in both groups, and the median
survival in the resected group was 18.5 months.
In a prospective study, Magnin et al. [46] studied
32 patients given preoperative chemoradiotherapy
between November 1996 and December 2001. Ra-
diation was given either as split course therapy of
30 Gy or standard fractionation therapy of 45 Gy over
5 weeks. Concurrent chemotherapy included contin-
uous infusion of 5-FU and a bolus of cisplatin. All
32 patients completed the entire course of chemor-
adiotherapy, with 2 patients suffering grade 3 toxi-
cities (weight loss and vomiting) and 1 patient died of
grade 4 infection with febrile neutropenia. Nineteen
patients underwent pancreatic resection, and one
patient in this group developed a late toxicity of acute
superior mesenteric artery thrombosis leading to
death. Radiation-induced alterations in the blood
vessels, although rare, are well known and have been
attributed to several mechanisms: intimal fibrosis, the
presence of fibrin and the accumulation of lipid-
containing macrophages [47]. The 2-year overall
survival rate in all 32 patients was 37.3%, with a
median survival of 16 months. The 2-year overall
survival rate in the 19 patients who underwent
resection was 59.3%, with a median survival of 30
months. The 2-year disease-free survival rate was
43.7%.
In a later series from the same group, Moutardier
et al. [48] described their experience with preopera-
tive chemoradiotherapy in patients with localized
pancreatic head ductal adenocarcinomas. Among 87
patients, 17 underwent resection alone, 39 patients
with potentially resectable cancers received preopera-
tive chemoradiotherapy, as did 31 with locally ad-
vanced cancer. In the 39 potentially resectable
patients, after completion of chemoradiotherapy,
only 23 remained resectable at restaging. The median
survival of patients who underwent chemoradiother-
apy followed by resection was significantly higher than
those who only underwent curative surgery (26.6
months vs 13.7 months; p5/0.005). There was a
significantly high rate of biliary stent-related problems
(23%) and two deaths due to superior mesenteric
artery thrombosis. However, they did not experience
high rates of chemoradiotherapy-related rehospitaliza-
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tion, unlike patients in some other series [49,50], nor
did they experience anastomotic complications of
pancreaticojejenostomies, and this could be related
to the radiation-induced pancreatic fibrosis [42]. On
pathological analysis, 8 of the 23 resected patients had
a major pathological response (35%) including two
complete responses (9%). Long-term follow-up
showed that none of the patients who received
chemoradiotherapy followed by resection developed
local recurrence.
In a study from the MD Anderson Cancer Centre,
the overall median survival was 21 months, with a
10% local recurrence rate in 132 patients [51]. In a
phase II trial by Pipas et al. [52] in patients with
resectable pancreas cancer, docetaxel and gemcita-
bine were given on days 1, 15 and 29, followed by
EBRT with 50.4 Gy at day 43, together with
gemcitabine twice weekly for 12 doses. In all, 24
patients with stage IIII disease were enrolled from
January 2002. Nineteen patients completed treat-
ment, with 11 responses (57%), including one com-
plete radiological response. Fourteen patients
underwent resection, with 11 of these having mar-
gin-negative resection, including 8 patients whose
disease was felt to be unresectable or borderline
unresectable prior to treatment. A dose finding study
on neoadjuvant chemoradiotherapy with gemcitabine
and accelerated hyperfractionated radiation in pa-
tients with potentially resectable pancreas cancer
was conducted by Nakamori et al. [53]. Their
recommended dose of gemcitabine was 800 mg/m2
combined with 36 Gy accelerated hyperfractionated
irradiation.
Neoadjuvant chemotherapy
In a phase II trial, Palmer et al. [54] from Birmingham
randomized 50 patients with resectable pancreas
cancer to receive either neoadjuvant gemcitabine or
gemcitabine with cisplatin. In this trial, 22/24 patients
in the gemcitabine arm received a median of 85% of
planned gemcitabine dose; 24/26 patients in the
gemcitabine plus cisplatin arm received a median of
88% of planned gemcitabine and 92% of planned
cisplatin dose. Grade III/IV haematological toxicity
was experienced by nine patients in each group.
Twenty-seven patients (54%) underwent resection;
18 patients had a bypass procedure and 5 patients had
no surgery due to progressive disease. The 1-year
survival from randomization was 46% in the gemci-
tabine arm and 61% for the gemcitabine and cisplatin
arm. A phase III trial of neoadjuvant gemcitabine and
cisplatin versus immediate surgery is planned.
Randomized controlled phase III trials assessing
neoadjuvant therapy are lacking, therefore this cannot
currently be endorsed as standard treatment.
Combination treatment
The rationale for the use of combination treatment
(chemoradiotherapy followed by chemotherapy) as
adjuvant treatment in resectable disease stems from a
randomized controlled trial done by the Gastrointest-
inal Tumour Study Group (GITSG) in the USA [8].
Forty-three patients were enrolled in this study, with
23 randomized to the adjuvant treatment arm and 21
to combined treatment in the form of split course
EBRT (40 Gy) and concurrent 5-FU, followed by
5-FU for 2 years. The study was terminated prema-
turely, both because of a low rate of accrual and
because of an increasingly large difference in survival
between the study arms. The median survival for the
adjuvant treatment group was 20 months, signifi-
cantly longer than the 11 months in the no adjuvant
treatment arm. However, five patients (24%) in the
adjuvant treatment arm did not receive planned
treatment owing to a prolonged postoperative recov-
ery. Because there were so few cases, a further 30
patients were registered (not randomized) to the
treatment arm and the median survival in this group
was 18 months, with a 2-year survival rate of 46%
[55]. Unfortunately, due to the small number of
patients, the 95% confidence intervals of the survival
curves were so large as to overlap with survival curves
in patients receiving no additional treatment. Thus no
convincing conclusion could be derived from this
study. The lack of a concurrent control group in the
follow-up study and inclusion of patients with body
and tail cancers of the pancreas are other flaws of the
GITSG studies.
Carducci et al. from John Hopkins initiated a phase
II trial to assess the toxicities of abdominal/hepatic
irradiation (liver 23.4 Gy; tumour bed 50.4 Gy) with
concurrent chemotherapy (continous infusion of
5-FU and leucovorin), followed after a gap of a month
by four cycles of chemotherapy (5-FU and leucov-
orin) in 14 patients who had undergone pancreatico-
duodenectomy for periampullary or pancreatic head
cancer [56]. Three patients developed grade 3/4
gastrointestinal toxicities during chemoradiotherapy,
while toxicities in the subsequent chemotherapy-alone
cycles were few. Abnormalities in liver function tests
were noted in 5060% of patients, but were asympto-
matic. In this study, 12/14 (85%) patients progressed,
with equal numbers of recurrences in the pancreatic
bed and in the liver over the 12-month median follow-
up. The median survival of patients was 417 days and
similar to that of patients who refused the trial and
received treatment as per the GITSG protocol.
Yeo et al. [3], in a prospective non-randomized
single institution study, compared two different post-
operative chemoradiation protocols to those of no
adjuvant treatment. The chemoradiation protocols
were either standard therapy (4045 Gy EBRT with
5-FU, followed by weekly bolus 5-FU for 4 months)
or intensive therapy (50.457.6 Gy EBRT to pan-
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creas bed with 23.427 Gy prophylactic hepatic
irradiation, given with and followed by infusional
5-FU plus leucovorin for 4 months). Between Octo-
ber 1991 and September 1995, 174 patients under-
went pancreaticoduodenectomy, with 1 postoperative
death. Ninety-nine patients opted for standard ther-
apy, 21 for intensive therapy and 53 declined therapy.
Patients in the postoperative adjuvant chemoradiation
group had a significantly better survival of 19.5
months compared with the 13.5 months in the no
adjuvant treatment group (p/ 0.003). When compar-
ison was made between the two chemoradiation
protocols, there was no significant difference in
survival for the intensive treatment group (median
survival 17.5 months) compared to the standard
therapy group (median survival 21 months; p/not
significant). The limitations of this study are its non-
randomized nature, their bias in favour of adjuvant
treatment and the fact that many patients receiving
standard therapy received it outside of the study
institution and hence toxicity data could not be fully
examined. Results from the Mayo Clinic also found
an improvement in outcome with adjuvant treatment,
but they experienced a high incidence of hepatic
failure and peritoneal seeding [57,58].
The UK Pancreatic Cancer Trials Group (UK-
PACA) studied combined treatment in a total of
40 patients from 9 institutions between 1987 and
1993 [59]. All patients underwent pancreatoduode-
nectomy, of whom 34 had ductal adenocarcinoma and
6 had ampullary tumours. Radiation therapy con-
sisted of a split course of 40 Gy separated by 2 weeks
and 5-FU was administered as a radiosensitizer, just
as in the GITSG regimen [8,55]. Two weeks after
radiotherapy, 5-FU was given as a bolus once a week
for a maximum of 24 weeks. No patient received the
full course of chemotherapy and a median of eight
treatments was given. The median survival for the 34
patients with pancreatic ductal adenocarcinoma was
13.2 months and the 5-year survival rate was 15%.
Patients with positive lymph nodes had a significantly
shorter survival time than those without lymph node
involvement. A positive resection margin was asso-
ciated with reduced survival only on multiple regres-
sion analysis once lymph node status was taken into
account. In this study no patient died or required
hospitalization because of 5-FU toxicity. It was felt
that the optimum length of follow-on treatment with
5-FU should not be beyond 6 months in the adjuvant
setting.
As gemcitabine is the recommended chemothera-
peutic agent for advanced pancreatic cancer, it is
increasingly being studied in the adjuvant treatment
setting. Kachnic et al. [60], in a prospective non-
randomized study, assessed the feasibility of adminis-
tering radiotherapy with concurrent 5-FU followed by
4 months of gemcitabine in both patients with
resectable (n/9) and locally advanced (n/14) pan-
creas cancer. Adjuvant gemcitabine was well toler-
ated, with no incidence of radiation recall. A phase II
study [61] evaluated the feasibility of postoperative
administration of gemcitabine alone for three courses,
followed by concurrent gemcitabine (at 300 mg/m2/
week) and irradiation (40 Gy) in patients undergoing
curative resection of pancreatic adenocarcinoma. All
patients completed chemotherapy with gemcitabine,
and all but two patients completed chemoradiother-
apy. One patient developed grade 4 vomiting and
thrombocytopenia while the other suffered disease
progression. The median disease-free survival and
overall survival was 6 and 15 months, respectively.
The reasons for administering gemcitabine before
combination therapy were that it could be started
soon after surgery, tackle micrometastatic dissemina-
tion and select out patients with rapid disease
progression. A phase I trial established that 39 Gy
was the maximum tolerated dose when used with full
dose gemcitabine after curative pancreatic resection
[62].
A prospective non-randomized trial from Germany
studied concurrent chemoradiotherapy with gemcita-
bine and cisplatin, followed by two cycles of cisplatin
and gemcitabine, in patients with R1 resection status
[63]. Haematological toxicities were the most com-
mon side effects in the 30 patients enrolled. The
median progression-free survival was 10.6 months,
and the median overall survival was 22.8 months.
Distant metastases occurred in 14 patients, and only
one patient had local failure during a median follow-
up of 15 months. The true benefit of this treatment
strategy is being assessed in an ongoing randomized
trial.
The Radiation Therapy Oncology Group Study
no. 97-04 is a phase III study of pre-and post-
chemoradiation 5-FU (for 3 months at a dose of
250 mg/m2/day) versus pre- and post-chemoradiation
gemcitabine (for 3 months at a dose of 1000 mg/m2/
day) for postoperative adjuvant treatment of resected
pancreatic adenocarcinoma. Accrual of /500 pa-
tients has been completed and the results are
awaited.
Meta-analysis
Stocken et al. [14] performed a meta-analysis inves-
tigating the roles of adjuvant chemoradiation and
chemotherapy following resection of pancreas ductal
adenocarcinoma on survival. Individual patient data
were available in four (875 patients) of the five
selected randomized controlled trials (total number
of patients with pancreatic adenocarcinoma/939).
Assessment of adjuvant chemotherapy trials revealed
a 25% significant reduction in the risk of death
(hazard ratio/0.75, CI: 0.64, 0.90, pstrat/0.001).
The median survival was 19 months with che-
motherapy and 13.5 months without. On the other
hand, there was no significant difference in the risk
of death with chemoradiation (hazard ratio/1.09,
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95% CI: 0.89, 1.32, pstrat/0.43). The median
survival was 15.8 months with chemoradiation and
15.2 months without. On subgroup analysis, che-
moradiation was more effective (x2/4.2, p/0.04)
and chemotherapy less effective (x2/7.3, p/0.007)
in patients with a positive resection margin. These
results provide strong evidence for institution of
adjuvant systemic chemotherapy following curative
surgery, although further RCTs may help decide
the optimal chemotherapeutic agent. Although not
recommended as a standard form of adjuvant
treatment, chemoradiation needs to be studied
further in the patients with positive resection
margins.
Conclusions
There is a definite role for adjuvant treatment of
pancreatic cancer following resection, from the avail-
able literature. There is controversy on either side of
the Atlantic over the form of treatment, i.e. che-
motherapy alone or combination therapy. A meta-
analysis [14] of randomized adjuvant therapy trials
concluded that chemotherapy is effective as adjuvant
treatment, but not chemoradiotherapy. It highlighted
the need for further studies with chemoradiation in
patients with R1 resection. The outcome of the
ESPAC-1 trial firmly supports the use of adjuvant
chemotherapy. The ESPAC-3 trial should answer the
question of the agent to be used in adjuvant che-
motherapy, i.e. gemcitabine or 5-FU. Currently there
does not seem to be a place for IORT alone in the
adjuvant setting. The rationale for combination ther-
apy is based on the results of the small GITSG study,
with its many shortcomings. The results of the RTOG
97-04 will answer the question on the agents to be
used and will assess results with more modern
radiation techniques, but will still not help in resolving
the controversy on chemotherapy versus combination
therapy. There are currently no results from large
RCTs to support the routine use of either regional
therapy or neoadjuvant treatment. However, the
encouraging results following regional therapy have
prompted the ESPAC-2 trial, which will shed further
light on this subject. The use of novel agents in
combination with current modalities is being tested
in phase II/III trials. Large co-operative group trials
can help develop better and more effective thera-
pies to improve the outlook and quality of life of
patients with this devastating disease.
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